CAPR - Capricor Therapeutics, Inc.
After hours:
Chart Events
Williams %R
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 4.4000 |
| Open | 4.4000 |
| Bid | 4.5000 x 1000 |
| Ask | 4.8900 x 800 |
| Day's Range | 4.4000 - 4.6200 |
| 52 Week Range | 3.3000 - 6.5800 |
| Volume | |
| Avg. Volume | 67,304 |
| Market Cap | 117.335M |
| Beta (5Y Monthly) | 4.02 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.1000 |
| Earnings Date | Aug 08, 2023 - Aug 14, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.00 |
Fair Value
Related Research
Simply Wall St.Capricor Therapeutics, Inc. (NASDAQ:CAPR) Shares Could Be 27% Above Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Capricor Therapeutics fair value estimate is US$3.18 Capricor...
GlobeNewswireCapricor Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
-Enrollment Continues to Progress in HOPE-3, the Phase 3 Clinical Trial of CAP-1002 in Duchenne Muscular Dystrophy (DMD); On Track to Report Interim Analysis in Fourth Quarter of 2023- -Plan to Present 24-Month HOPE-2 Open Label Extension Data in Second Quarter of 2023- -To Host Conference Call and Webcast Today at 4:30 p.m. ET- SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-b
- GlobeNewswire
Capricor Therapeutics to Present First Quarter 2023 Financial Results and Recent Corporate Update on May 11
Company to Host Conference Call, May 11, 2023, at 4:30 p.m. ETSAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, will release its financial results for the first quarter ended March 31, 2023, after the market close on Thursday, May 11, 2023. Management will then host a webcast and conference
- GlobeNewswire
Capricor Announces Peer-Reviewed Publication Demonstrating the Therapeutic Potential of Exosome-Based Multivalent Vaccine Developed from its StealthX™ Platform
-Capricor’s StealthX™ Exosome Platform Designed to Support the Advancement of Next Generation Vaccines and Therapeutics-SAN DIEGO, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today the publication of a preclinical study in Microbiology Spectrum, a leading peer-reviewed scient
- GlobeNewswire
Capricor Therapeutics Presents at 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Late-Breaking Presentation Highlighted Positive18-Month Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy PatientsSAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today that the Company presented the 18-month results from its HOPE-2 open-
- Simply Wall St.
When Will Capricor Therapeutics, Inc. (NASDAQ:CAPR) Become Profitable?
With the business potentially at an important milestone, we thought we'd take a closer look at Capricor Therapeutics...
Insider MonkeyCapricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2022 Earnings Call Transcript
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2022 Earnings Call Transcript March 15, 2023 Operator: Good afternoon, and welcome to Capricor Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. As a reminder, this conference […]
- GlobeNewswire
Capricor Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
-Enrollment Continues to Progress in HOPE-3, the Phase 3 Clinical Trial of CAP-1002 in Duchenne Muscular Dystrophy (DMD); Plan to Report on Interim Analysis in Q4 2023- -Held Type-B CMC Meeting with U.S. Food and Drug Administration (FDA) Regarding Pathway Towards Biologics License Application (BLA) for CAP-1002 in DMD- -Expanded Partnership with Nippon Shinyaku to Japan to Leverage Commercial DMD Franchise with $12 Million Upfront and Additional Potential Milestone Payments of up to $89 Million
- GlobeNewswire
Capricor Therapeutics to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on March 15
-Company to Host Conference Call, March 15, 2023, at 4:30 p.m. ET-SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, will release its financial results for the fourth quarter and full year ended December 31, 2022, after the market close on Wednesday, March 15, 2023. Management will then ho
- GlobeNewswire
Capricor Therapeutics Receives Clinical Research Forum’s 2023 Top Ten Clinical Research Achievement Award
-HOPE-2 Trial Recognized as an Outstanding Accomplishment in Research Advancement-SAN DIEGO, March 02, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today that the Company’s HOPE-2 study with lead asset, CAP-1002, for treating Duchenne muscular dystrophy (DMD) has been named as a recipient of th
- GlobeNewswire
Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in Japan
-Expands Partnership with Nippon Shinyaku to Japan to Leverage Deep Experience in Drug Development for Rare Diseases and Commercial DMD Franchise- -Capricor to Receive an Upfront Payment of $12 Million, Additional Potential Milestone Payments of up to $89 Million as well as Meaningful Double-Digit Percentage of Revenue Based on Product Sales- SAN DIEGO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cel
GlobeNewswireCapricor Therapeutics Announces Positive 18-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients
-Statistically Significant Results in Performance of the Upper Limb PUL 2.0 (p=0.02) Extended to 18 Months, Demonstrating Long-Term Benefit in Skeletal Muscle Function- -Results Continue to Suggest Potential Disease Modification in Duchenne Muscular Dystrophy (DMD)- -Capricor to Host Webinar in Conjunction with Parent Project Muscular Dystrophy (PPMD) Today at 1:00 p.m. ET- SAN DIEGO, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the d
- GlobeNewswire
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Provide Recent Updates on CAP-1002 Program
-Company to present 18-month data results from ongoing HOPE-2 open label extension trial of CAP-1002 in patients with Duchenne muscular dystrophy- -Webinar to be held on Wednesday, January 25, 2023 at 1:00 p.m. ET- SAN DIEGO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today that the C
BenzingaCapricor Highlights Preclinical Data From Its Closed COVID-19 Vaccine Study
Capricor Therapeutics (NASDAQ: CAPR) announced the publication of a preclinical study online in bioRxiv and explored Capricor's proprietary StealthX exosome platform's therapeutic potential, generating two vaccine candidates (STX-S and STX-N). The vaccines independently and in combination (STX-S+N) induced a strong immune response against two SARS-CoV-2 proteins, spike and nucleocapsid. Results showed that this multivalent, protein-based vaccine candidate has the potential to achieve potent, lon
- GlobeNewswire
Capricor Announces Publication Highlighting New Advances for its Engineered Exosome Platform
-StealthX™ Exosome Platform Shows Multivalent Vaccine Induces Long-Lasting Immunity to Multiple SARS-CoV-2 Proteins- SAN DIEGO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today the publication of a preclinical study highlighting new advances for its engineered exosome program. The dat
ZacksCapricor (CAPR) Upgraded to Buy: What Does It Mean for the Stock?
Capricor (CAPR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Simply Wall St.
Despite shrinking by US$18m in the past week, Capricor Therapeutics (NASDAQ:CAPR) shareholders are still up 194% over 3 years
Some Capricor Therapeutics, Inc. ( NASDAQ:CAPR ) shareholders are probably rather concerned to see the share price fall...
TipRanks2 “Strong Buy” Penny Stocks That Could Rally All the Way to $15
Which stocks are either a fan favorite or a must-avoid? Penny stocks. These tickers going for less than $5 apiece are particularly divisive on Wall Street, with those in favor as well as the naysayers laying out strong arguments. These names are too appealing for the risk-tolerant investor to ignore. Given the low prices, you get more for your money. On top of this, even minor share price appreciation can translate to massive percentage gains, and thus, major returns for investors. However, ther
- Simply Wall St.
Capricor Therapeutics Third Quarter 2022 Earnings: Beats Expectations
Capricor Therapeutics ( NASDAQ:CAPR ) Third Quarter 2022 Results Key Financial Results Net loss: US$6.37m (loss widened...
ZacksCapricor Therapeutics (CAPR) Reports Q3 Loss, Tops Revenue Estimates
Capricor (CAPR) delivered earnings and revenue surprises of 7.14% and 279.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- Thomson Reuters StreetEvents
Edited Transcript of CAPR.OQ earnings conference call or presentation 10-Nov-22 9:30pm GMT
Q3 2022 Capricor Therapeutics Inc Earnings Call
- GlobeNewswire
Capricor Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-Enrollment Continues to Progress in HOPE-3, the Pivotal Phase 3 Clinical Trial of CAP-1002 in Duchenne Muscular Dystrophy- -Presented Positive One-Year Safety and Efficacy Results From HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients at World Muscle Society 2022- -Presented New Advances in Engineered Exosome Platform at Exosome-Based Therapeutic Development Summit- -To Host Conference Call and Webcast Today at 4:30 p.m. ET- SAN DIEGO, Nov. 10, 2022 (GLOBE NE
- GlobeNewswire
Capricor Therapeutics to Present Third Quarter 2022 Financial Results and Recent Corporate Update on November 10
Company to Host Conference Call, November 10, 2022, at 4:30 p.m. ETSAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, will release its financial results for the third quarter ended September 30, 2022, after the market close on Thursday, November 10, 2022. Management will then host a webcast
- GlobeNewswire
Capricor Therapeutics to Present One-Year Results from HOPE-2 Open Label Extension Study at World Muscle Society 2022
SAN DIEGO, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today that the Company will present one-year safety and efficacy results from its HOPE-2 open-label extension study with lead asset CAP-1002 for treating Duchenne muscular dystrophy (DMD). These data will be featured in a poster pr
- GlobeNewswire
Capricor Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today that the Company will present at the following upcoming investor conferences in September. Conference and presentation details are as follows: H.C. Wainwright 24th Annual Global Investment Conference (September 12 – 14, 2022